Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Group Core Oplnc to grow high single digit driven by business
momentum and PluvictoⓇ manufacturing capacity expansion
FINANCIAL PROFILE
2023 key drivers of core operating income (Group)
Vs. PY (cc) Illustrative
+ In-market growth drivers to
continue growing strongly
+ Recent launches to further accelerate,
PluvictoⓇ benefiting from manufacturing
capacity expansion
+ China growth expected to accelerate
benefiting from return to normal in H2
+ Simplified organizational model to
deliver continued SG&A savings
+ Ongoing productivity programs
-
-
Impact of inflation expected to
continue
Gx erosion expected to increase due
to GilenyaⓇ US and LucentisⓇ EU
Stand-up investments to transition
Sandoz to a standalone company
27 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation